COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,843 Articles (22,553 medRxiv, 8,290 bioRxiv)

Most recent first Previous |  Page 490: Articles 4891-4900  | Next

An alpaca-derived nanobody neutralizes the SARS-CoV-2 omicron variant
Modhiran, N., Lauer, S. M., Amarilla, A. A., Hewins, P., van den Broek, S. I. L., Low, Y. S., Thakur, N., Liang, B., Nieto, G. V., Jung, J., Paramitha, D., Isaacs, A., de Sng, J., Song, D., Jorgensen, J., Cheuquemilla, Y., Burger, J., Andersen, I. V., Himelreichs, J., Jara, R., MacLoughlin, R., Miranda-Chacon, Z., Chana-Cuevas, P., Kramer, V., Spahn, C. M. T., Mielke, T., Khromykh, A. A., Munro, T., Jones, M., Young, P. R., Chappell, K., Bailey, D., Kjaer, A., Herth, M. M., Jurado, K. A., Schwefel, D., Rojas-Fernandez, A., Watterson, D.
10.1101/2022.12.27.521990 — Posted: 2022-12-27
ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses
Hoffmann, M. A., Yang, Z., Huey-Tubman, K. E., Cohen, A. A., Gnanapragasam, P. N., Nakatomi, L. M., Storm, K. N., Moon, W. J., Lin, P. J., Bjorkman, P. J.
10.1101/2022.12.26.521940 — Posted: 2022-12-27
Prior infection- and/or vaccine-induced protection against Omicron BA.1, BA.2 and BA.4/BA.5-related hospitalisations in older adults: a test-negative case-control study in Quebec, Canada
Carazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Fafard, J. M., Gilca, R., Talbot, D., Ouakki, M., Febriani, Y., Deceuninck, G., De Wals, P., De Serres, G.
10.1101/2022.12.21.22283740 — Posted: 2022-12-27
Changes in depression and anxiety among people with cognitive impairment and dementia during the COVID-19 pandemic: Analysis of the English Longitudinal Study of Ageing
Beach, B., Steptoe, A., Zaninotto, P.
10.1101/2022.12.23.22283884 — Posted: 2022-12-27
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
Weidenbacher, P. A.- B., Sanyal, M., Friedland, N., Tang, S., S Arunachalam, P., Hu, M., Kumru, O. S., Morris, M. K., Fontenot, J., Shirreff, L., Do, J., Cheng, Y.-C., Vasudevan, G., Feinberg, M. B., Villinger, F. J., Hanson, C., Joshi, S. B., Volkin, D. B., Pulendran, B., Kim, P. S.
10.1101/2022.12.25.521784 — Posted: 2022-12-26
Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19
Bello, S. O., Yunusa, A., Adamu, A. A., Imam, M. U., Bello, M. B., Shuaibu, A. B., Igumbor, E. U., Habib, Z. G., Popoola, M. A., Ochu, C. L., Bello, A. Y., Deeni, Y. Y., Okoye, I.
10.1101/2022.12.25.521651 — Posted: 2022-12-26
Amplification and extraction free quantitative detection of viral nucleic acids and single-base mismatches using magnetic signal amplification circuit
Roesch, E. L., Sack, R., Chowdhury, M. S., Wolgast, F., Schilling, M., Viereck, T., Lak, A.
10.1101/2022.12.24.521858 — Posted: 2022-12-26
In Vitro Inhibition of SARS-CoV-2 Infection by Bromhexine hydrochloride
Martins, R., Ferreira, I., Jorge, D. M., Almeida, L., Souza, J. d. P., Pontelli, M. C., Castro, I. A., Melquiades, T., Mendes Viana, R. M., Zamboni, D. S., Marcato, P., Arruda, E.
10.1101/2022.12.23.521817 — Posted: 2022-12-26
Emerging variants of SARS-CoV-2 NSP10 highlight strong functional conservation of its binding to two non-structural proteins, NSP14 and NSP16
Wang, H., Rizvi, S. R. A., Dong, D., Lou, J., Wang, Q., Sopipong, W., Su, Y., Najar, F., Agarwal, P., Kozielski, F. G., Haider, S.
10.1101/2022.12.23.521761 — Posted: 2022-12-26
A large-scale serological survey in pets from October 2020 through June 2021 in France shows significantly higher exposure to SARS-CoV-2 in cats
Fritz, M., Elguero, E., Becquart, P., de Riols de Fonclare, D., Garcia, D., Beurlet, S., Denolly, S., Boson, B., Rosolen, S. G., Cosset, F.-L., Briend-Marchal, A., Legros, V., Leroy, E. M.
10.1101/2022.12.23.521567 — Posted: 2022-12-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).